Achillion Pharmaceuticals (NASDAQ:ACHN) was downgraded by research analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued to investors on Tuesday.

Several other research firms have also weighed in on ACHN. Barclays raised shares of Achillion Pharmaceuticals from an “underweight” rating to an “equal weight” rating and set a $5.00 price objective on the stock in a research note on Monday, May 21st. Zacks Investment Research raised shares of Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, May 29th. Finally, ValuEngine raised shares of Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, June 1st. One investment analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the company. Achillion Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $4.38.

Achillion Pharmaceuticals stock opened at $3.16 on Tuesday. Achillion Pharmaceuticals has a fifty-two week low of $2.33 and a fifty-two week high of $4.82. The company has a market cap of $457.33 million, a P/E ratio of -5.10 and a beta of 1.03.

Achillion Pharmaceuticals (NASDAQ:ACHN) last released its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.01. analysts forecast that Achillion Pharmaceuticals will post -0.52 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently made changes to their positions in ACHN. Acadian Asset Management LLC bought a new position in Achillion Pharmaceuticals in the second quarter valued at approximately $135,000. Cubist Systematic Strategies LLC bought a new position in Achillion Pharmaceuticals in the second quarter valued at approximately $147,000. BlueMountain Capital Management LLC bought a new position in Achillion Pharmaceuticals in the second quarter valued at approximately $159,000. Element Capital Management LLC bought a new position in Achillion Pharmaceuticals in the first quarter valued at approximately $163,000. Finally, New York State Common Retirement Fund lifted its stake in Achillion Pharmaceuticals by 24.1% in the first quarter. New York State Common Retirement Fund now owns 146,800 shares of the biopharmaceutical company’s stock valued at $545,000 after buying an additional 28,500 shares in the last quarter. 78.37% of the stock is currently owned by hedge funds and other institutional investors.

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy.

Recommended Story: Price to Earnings Ratio (PE), For Valuing Stocks

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.